Story perspectives

FDA Panel Recommends Grail’s Galleri for Premarket Approval

By Drooid · Sep 24, 2026, 3:26 PM UTC · How we work

Summary

Story summary

U.S. FDA panel voted to recommend Grail’s Galleri test for premarket approval.
Galleri is a multi-cancer early detection blood assay.
The assay detects circulating tumour DNA and other abnormal molecules in blood and urine.
Hong Kong doctors remain cautious about the test’s clinical value, hindering wider adoption despite U.S. endorsement.

1 of 1

Story summary

U.S. FDA panel voted to recommend Grail’s Galleri test for premarket approval.
Galleri is a multi-cancer early detection blood assay.
The assay detects circulating tumour DNA and other abnormal molecules in blood and urine.
Hong Kong doctors remain cautious about the test’s clinical value, hindering wider adoption despite U.S. endorsement.